The prospects for the use of Mexidol for the treatment of patients suffering from neurosenate hearing loss and cerebrovascular failure

Author:
N.L. KUNELSKAYA, Yu.V. LEVINA, E.S. YANYUSHKINA, D.S. OGORODNIKOV, E.V. LARIONOVA

Place of publication:
VESTNIK OTOLARYNGOLOGII, 2019, Vol. 84, No. 6

Abstract:
In sensorineural hearing loss with vascular etiology, hearing changes may arise as a consequence of vertebrobasilar insufficiency of various etiologies. The etiology and pathogenesis of chronic sensorineural hearing loss suggest the potential for the use of neuroprotective agents capable of activating the structure and function of neuronal structures in the auditory tract. Ethyl methylhydroxypyridine succinate, with its comprehensive pharmacological properties and broad spectrum of effects at the neuronal and vascular levels, can be used in the treatment of hearing and speech impairment. Keywords: hearing loss, sensorineural hearing loss, auditory rehabilitation, ethyl methylhydroxypyridine succinate.

Actual

Actual

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com